DONATE TODAY
To Increase Patient Access

October 3, 2022

INCREASING PATIENT DISEASE EDUCATION, AWARENESS & OUTREACH FOR GREATER ACCESS TO ADVANCED DIAGNOSTICS, SPECIALISTS AND TREATMENT OPTIONS/CLINICAL TRIALS WITH ENDEAVOR BIOMEDICINES

The End Brain Cancer Initiative (EBCI) is pleased to bring you this “Cover Tip” focused on Next Generation Sequencing (NGS)

If you have a solid tumor, you may benefit from an additional test called Next Generation Sequencing (NGS). NGS testing looks at the genes associated with cancer. This test may show if a gene is mutated and causing your cancer to grow. This can help your doctor make treatment decisions. One gene mutation that NGS may detect is called PTCH1-Loss of Function (LOF).

QR code for  endeavor

If you have had Next Generation Sequencing testing and are positive for the PTCH1-LOF mutation or if you want to learn more about NGS Testing, type into your browser: https://endbraincancer.org/endeavor
OR scan this QR Code.

Photo of Dellann

Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org

EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram